With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
The usually conservative group spends big on Dicerna – but others might be interested too.